Manufacturer of Controlled Substances; Notice of Application, 46232-46233 [E9-21525]
Download as PDF
<![CDATA[
46232
Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21522 Filed 9–4–09; 8:45 am]
27709, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedules I and II:
Drug
BILLING CODE 4410–09–P
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Cocaine (9041) .............................
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on June 26,
2009, Noramco Inc., Division of OrthoMcNeil, Inc., 500 Swedes Landing Road,
Wilmington, Delaware 19801–4417,
made application by letter to the Drug
Enforcement Administration (DEA) for
registration as a bulk manufacturer of
Noroxymorphone (9668), a basic class of
controlled substance listed in schedule
II.
The company plans to bulk
manufacture the listed controlled
substance as a reference standard for
distribution to its customers which are
analytical laboratories.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than November 9, 2009.
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21524 Filed 9–4–09; 8:45 am]
DEPARTMENT OF JUSTICE
The Institute will manufacture small
quantities of cocaine and marihuana
derivatives for use by their customers in
analytical kits, reagents, and reference
standards as directed by the National
Institute on Drug Abuse.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 9, 2009.
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21526 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Drug Enforcement Administration
Drug
jlentini on DSKJ8SOYB1PROD with NOTICES
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 18, 2009,
Research Triangle Institute, Kenneth H.
Davis Jr., Hermann Building, East
Institute Drive, P.O. Box 12194,
Research Triangle, North Carolina
17:32 Sep 04, 2009
Jkt 217001
I
I
II
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 1, 2009,
Alltech Associates Inc., 2051 Waukegan
Road, Deerfield, Illinois 60015, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
BILLING CODE 4410–09–P
VerDate Nov<24>2008
Schedule
Schedule
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
4-Methylaminorex (cis isomer)
(1590).
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
2,5-Dimethoxy-4-(n)propylthiophenethylamine
(7348).
PO 00000
Frm 00153
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
Drug
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
4-Methoxyamphetamine (7411) ...
Alpha-methyltryptamine (7432) ....
Bufotenine (7433) .........................
Diethyltryptamine (7434) ..............
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
N-Ethyl-1-phenylcyclohexylamine
(7455).
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-Phenylcyclohexylamine (7460)
1-[1-(2Thienyl)cyclohexyl]piperidine
(7470).
Normorphine (9313) .....................
Methamphetamine (1105) ............
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
1Piperidinocyclohexanecarbonitrile (8603).
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Dihydromorphine (9145) ...............
Ecgonine (9180) ...........................
Meperidine intermediate-B (9233)
Noroxymorphone (9668) ..............
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
high purity drug standards used for
analytical application only in clinical,
toxicological, and forensic laboratories.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
E:\FR\FM\08SEN1.SGM
08SEN1
46233
Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices
Springfield, Virginia 22152; and must be
filed no later than November 9, 2009.
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 17, 2009, and
published in the Federal Register on
April 29, 2009, (74 FR 19598), Cambrex
Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21525 Filed 9–4–09; 8:45 am]
DEPARTMENT OF JUSTICE
By Notice dated April 17, 2009, and
published in the Federal Register on
April 29, 2009, (74 FR 19597), Rhodes
Technologies, 498 Washington Street,
Coventry, Rhode Island 02816, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 7, 2009,
National Center for Natural Products
Research—NIDA MProject, University of
Mississippi, 135 Coy Waller Lab
Complex, University, Mississippi 38677,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I:
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Codeine (9050) .............................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
Tetrahydrocannabinols (7370) .....
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Fentanyl (9801) ............................
Schedule
I
II
II
II
II
II
II
II
II
II
II
II
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21528 Filed 9–4–09; 8:45 am]
I
I
The company plans to cultivate
marihuana for the National Institute on
Drug Abuse for research approved by
the Department of Health and Human
Services.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 9, 2009.
Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21523 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–09–P
17:32 Sep 04, 2009
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–21533 Filed 9–4–09; 8:45 am]
BILLING CODE 4410–09–P
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
VerDate Nov<24>2008
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambrex Charles City, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cambrex Charles City, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
The company plans to manufacture
the listed controlled substances in bulk
for conversion and sale to dosage form
manufacturers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Rhodes Technologies to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Rhodes Technologies to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
BILLING CODE 4410–09–P
Drug
jlentini on DSKJ8SOYB1PROD with NOTICES
Schedule
Jkt 217001
PO 00000
Frm 00154
Fmt 4703
Sfmt 4703
E:\FR\FM\08SEN1.SGM
08SEN1
]]>Agencies
[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Pages 46232-46233]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-21525]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on July 1, 2009, Alltech
Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
N,N-Dimethylamphetamine (1480)............. I
4-Methylaminorex (cis isomer) (1590)....... I
Alpha-ethyltryptamine (7249)............... I
Lysergic acid diethylamide (7315).......... I
2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine (7348).
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
3,4-Methylenedioxyamphetamine (7400)....... I
N-Hydroxy-3,4-methylenedioxyamphetamine I
(7402).
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (MDMA) I
(7405).
4-Methoxyamphetamine (7411)................ I
Alpha-methyltryptamine (7432).............. I
Bufotenine (7433).......................... I
Diethyltryptamine (7434)................... I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
5-Methoxy-N,N-diisopropyltryptamine (7439). I
N-Ethyl-1-phenylcyclohexylamine (7455)..... I
1-(1-Phenylcyclohexyl)pyrrolidine (7458)... I
1-Phenylcyclohexylamine (7460)............. I
1-[1-(2-Thienyl)cyclohexyl]piperidine I
(7470).
Normorphine (9313)......................... I
Methamphetamine (1105)..................... II
Phencyclidine (7471)....................... II
Phenylacetone (8501)....................... II
1-Piperidinocyclohexanecarbonitrile (8603). II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Dihydromorphine (9145)..................... II
Ecgonine (9180)............................ II
Meperidine intermediate-B (9233)........... II
Noroxymorphone (9668)...................... II
------------------------------------------------------------------------
The company plans to manufacture high purity drug standards used
for analytical application only in clinical, toxicological, and
forensic laboratories.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the proposed registration pursuant to 21 CFR
1301.33(a).
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive,
[[Page 46233]]
Springfield, Virginia 22152; and must be filed no later than November
9, 2009.
Dated: August 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-21525 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P
